FIBROBIOLOGICS, INC.

Highlights FibroBiologics, Inc.

Equities

FBLG

US31573L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
11.35 ^USD	-3.81%		+22.17%	0.00%

May. 14	FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	Apr. 25	CI
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA	Apr. 04	CI
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	Feb. 20	CI
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases	Feb. 13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW